Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05653349




Registration number
NCT05653349
Ethics application status
Date submitted
23/11/2022
Date registered
16/12/2022
Date last updated
25/11/2024

Titles & IDs
Public title
Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)
Scientific title
A Phase III, Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (VAYHIT1)
Secondary ID [1] 0 0
CVAY736I12301
Universal Trial Number (UTN)
Trial acronym
VAYHIT1
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Primary Immune Thrombocytopenia (ITP) 0 0
Condition category
Condition code
Blood 0 0 0 0
Haematological diseases
Blood 0 0 0 0
Other blood disorders
Inflammatory and Immune System 0 0 0 0
Autoimmune diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Other - Ianalumab
Treatment: Drugs - Placebo
Treatment: Drugs - Corticosteroids

Experimental: Ianalumab Lower dose - Lower dose of ianalumab administered intravenously with corticosteroids oral or parental (if clinically justified)

Experimental: Ianalumab Higher dose - Higher dose of ianalumab administered intravenously with corticosteroids oral or parental (if clinically justified)

Placebo comparator: Placebo - Placebo administered intravenously with corticosteroids oral or parental (if clinically justified)


Treatment: Other: Ianalumab
Intravenous infusion, prepared from concentrate solution

Treatment: Drugs: Placebo
Intravenous infusion, prepared from matching placebo

Treatment: Drugs: Corticosteroids
Oral or parental (if clinically justified)
Intervention code [1] 0 0
Treatment: Other
Intervention code [2] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Time from randomization to treatment failure (TTF)
Timepoint [1] 0 0
Randomization to end of study (up to 39 months after randomization of last patient)
Secondary outcome [1] 0 0
Complete Response (CR) rate in each treatment group
Timepoint [1] 0 0
Randomization to end of study (up to 39 months after randomization of last patient)
Secondary outcome [2] 0 0
Response (R) rate in each treatment group
Timepoint [2] 0 0
Randomization to end of study (up to 39 months after randomization of last patient)
Secondary outcome [3] 0 0
Time to complete response in each treatment group
Timepoint [3] 0 0
Randomization to end of study (up to 39 months after randomization of last patient)
Secondary outcome [4] 0 0
Duration of response in each treatment group
Timepoint [4] 0 0
Randomization to end of study (up to 39 months after randomization of last patient)
Secondary outcome [5] 0 0
Stable response at 6 months
Timepoint [5] 0 0
At 6 months
Secondary outcome [6] 0 0
Stable response at 1 year
Timepoint [6] 0 0
At 1 year
Secondary outcome [7] 0 0
Percentage of participants with bleeding events overall and by World Health Organization (WHO) bleeding scale severity
Timepoint [7] 0 0
Randomization to end of study (up to 39 months after randomization of last patient)
Secondary outcome [8] 0 0
Number of participants with bleeding events overall and by World Health Organization (WHO) bleeding scale severity
Timepoint [8] 0 0
Randomization to end of study (up to 39 months after randomization of last patient)
Secondary outcome [9] 0 0
Number of participants receiving rescue treatment (cummulative dose/duration of steroids exposure)
Timepoint [9] 0 0
Randomization to end of study (up to 39 months after randomization of last patient)
Secondary outcome [10] 0 0
Percentage of participants receiving rescue treatment (cummulative dose/duration of steroids exposure)
Timepoint [10] 0 0
Randomization to end of study (up to 39 months after randomization of last patient)
Secondary outcome [11] 0 0
Cumulative dose/duration of steroids exposure
Timepoint [11] 0 0
From screening to end of study (up to 39 months after randomization of last patient)
Secondary outcome [12] 0 0
Change from baseline on T scores of the PROMIS SF v1.0 Fatigue 13a
Timepoint [12] 0 0
From screening (baseline) till end of study (up to 39 months after randomization of last patient)
Secondary outcome [13] 0 0
Change from baseline in ITP-PAQ domain scores
Timepoint [13] 0 0
From screening (baseline) till end of study (up to 39 months after randomization of last patient)
Secondary outcome [14] 0 0
Change from baseline in frequency of CD19+ B cell counts
Timepoint [14] 0 0
Randomization to end of study (up to 39 months after randomization of last patient)
Secondary outcome [15] 0 0
Change from baseline in absolute number of CD19+ B cell counts
Timepoint [15] 0 0
Randomization to end of study (up to 39 months after randomization of last patient)
Secondary outcome [16] 0 0
Time to first occurrence of B-cell recovery
Timepoint [16] 0 0
Randomization to end of study (up to 39 months after randomized of last patient)
Secondary outcome [17] 0 0
Change from baseline in inmmunoglobulins
Timepoint [17] 0 0
Randomization to end of study (up to 39 months after last randomized patients)
Secondary outcome [18] 0 0
PK parameters: AUClast
Timepoint [18] 0 0
After first dose (pre-dose, 2, 168, 336 and 504 hours post dose) and after last dose (pre-dose, 2, 336, 672, 1344, 2016, 3360 hours post dose)
Secondary outcome [19] 0 0
PK parameter: AUCtau
Timepoint [19] 0 0
After first dose (pre-dose, 2, 168, 336 and 504 hours post dose) and after last dose (pre-dose, 2, 336, 672, 1344, 2016, 3360 hours post dose)
Secondary outcome [20] 0 0
PK parameters: Cmax
Timepoint [20] 0 0
After first dose (pre-dose, 2, 168, 336 and 504 hours post dose) and after last dose (pre-dose, 2, 336, 672, 1344, 2016, 3360 hours post dose)
Secondary outcome [21] 0 0
PK parameters: Tmax
Timepoint [21] 0 0
After first dose (pre-dose, 2, 168, 336 and 504 hours post dose) and after last dose (pre-dose, 2, 336, 672, 1344, 2016, 3360 hours post dose)
Secondary outcome [22] 0 0
PK parameters: Accumulation ratio Racc
Timepoint [22] 0 0
After last dose (pre-dose, 2, 336, 672, 1344, 2016, 3360 hours post dose)
Secondary outcome [23] 0 0
Incidence of anti-ianalumab antibodies in serum (ADA assay) over time
Timepoint [23] 0 0
Up to Week 33
Secondary outcome [24] 0 0
Titer of anti-ianalumab antibodies in serum (ADA assay) over time
Timepoint [24] 0 0
Up to Week 33

Eligibility
Key inclusion criteria
* Signed informed consent prior to participation in the study.
* Male or female participants aged 18 years and older on the day of signing informed consent
* Primary ITP diagnosed within 3 months before initiating first-line ITP therapy (corticosteroids, IVIG)
* Platelet count below 30 G/L before starting any first-line ITP therapy (corticosteroids, IVIG)
* Response (platelet count >=50 G/L) to corticosteroids (+/- IVIG) at any time prior to randomization. Note: Platelet count measured within 7 days of platelet transfusion will not be considered as response.

Key
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Evans syndrome or any other cytopenia (patients with anemia related to bleeding or iron deficiency are eligible)
* Current life-threatening bleeding
* Previous ITP treatment, including splenectomy, except for corticosteroids and/or IVIG initiated as first-line therapy for up to 28 days before randomization and rescue corticosteroids and/or IVIG given prior to confirmed diagnosis of primary ITP .
* Prior use of B-cell depleting therapy (e.g., rituximab).
* Absolute neutrophil count below 1.0 G/L at randomization
* Participants with concurrent coagulation disorders and/or receiving anti-platelet or anticoagulant medication with an exemption of low dose of acetylsalicylic acid

Other protocol-defined Inclusion/Exclusion may apply.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
6/03/2023
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
18/12/2028
Actual
Sample size
Target
225
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
ACT,QLD,VIC
Recruitment hospital [1] 0 0
Novartis Investigative Site - Canberra
Recruitment hospital [2] 0 0
Novartis Investigative Site - Wooloongabba
Recruitment hospital [3] 0 0
Novartis Investigative Site - Clayton
Recruitment hospital [4] 0 0
Novartis Investigative Site - Melbourne
Recruitment postcode(s) [1] 0 0
2605 - Canberra
Recruitment postcode(s) [2] 0 0
4102 - Wooloongabba
Recruitment postcode(s) [3] 0 0
3168 - Clayton
Recruitment postcode(s) [4] 0 0
3004 - Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Illinois
Country [6] 0 0
United States of America
State/province [6] 0 0
Indiana
Country [7] 0 0
United States of America
State/province [7] 0 0
Maryland
Country [8] 0 0
United States of America
State/province [8] 0 0
Michigan
Country [9] 0 0
United States of America
State/province [9] 0 0
Minnesota
Country [10] 0 0
United States of America
State/province [10] 0 0
Montana
Country [11] 0 0
United States of America
State/province [11] 0 0
New Jersey
Country [12] 0 0
United States of America
State/province [12] 0 0
New York
Country [13] 0 0
United States of America
State/province [13] 0 0
Ohio
Country [14] 0 0
United States of America
State/province [14] 0 0
Oklahoma
Country [15] 0 0
United States of America
State/province [15] 0 0
Pennsylvania
Country [16] 0 0
United States of America
State/province [16] 0 0
Rhode Island
Country [17] 0 0
United States of America
State/province [17] 0 0
Texas
Country [18] 0 0
United States of America
State/province [18] 0 0
Utah
Country [19] 0 0
Argentina
State/province [19] 0 0
Buenos Aires
Country [20] 0 0
Argentina
State/province [20] 0 0
San Miguel De Tucuman
Country [21] 0 0
Argentina
State/province [21] 0 0
Buenos aires
Country [22] 0 0
Argentina
State/province [22] 0 0
Cordoba
Country [23] 0 0
Austria
State/province [23] 0 0
Tyrol
Country [24] 0 0
Austria
State/province [24] 0 0
Salzburg
Country [25] 0 0
Austria
State/province [25] 0 0
Wien
Country [26] 0 0
Belgium
State/province [26] 0 0
Brasschaat
Country [27] 0 0
Belgium
State/province [27] 0 0
Brugge
Country [28] 0 0
Belgium
State/province [28] 0 0
Leuven
Country [29] 0 0
Belgium
State/province [29] 0 0
Roeselare
Country [30] 0 0
Bulgaria
State/province [30] 0 0
Plovdiv
Country [31] 0 0
Bulgaria
State/province [31] 0 0
Sofia
Country [32] 0 0
Bulgaria
State/province [32] 0 0
Varna
Country [33] 0 0
China
State/province [33] 0 0
Beijing
Country [34] 0 0
China
State/province [34] 0 0
Chongqing
Country [35] 0 0
China
State/province [35] 0 0
Guangdong
Country [36] 0 0
China
State/province [36] 0 0
Henan
Country [37] 0 0
China
State/province [37] 0 0
Hubei
Country [38] 0 0
China
State/province [38] 0 0
Hunan
Country [39] 0 0
China
State/province [39] 0 0
Jiangsu
Country [40] 0 0
China
State/province [40] 0 0
Jiangxi
Country [41] 0 0
China
State/province [41] 0 0
Shaanxi
Country [42] 0 0
China
State/province [42] 0 0
Shanxi
Country [43] 0 0
China
State/province [43] 0 0
Sichuan
Country [44] 0 0
China
State/province [44] 0 0
Yunnan
Country [45] 0 0
China
State/province [45] 0 0
Zhejiang
Country [46] 0 0
China
State/province [46] 0 0
Bengbu
Country [47] 0 0
China
State/province [47] 0 0
Dalian
Country [48] 0 0
China
State/province [48] 0 0
Jinan
Country [49] 0 0
China
State/province [49] 0 0
Shijiazhuang
Country [50] 0 0
China
State/province [50] 0 0
Tianjin
Country [51] 0 0
Czechia
State/province [51] 0 0
Poruba
Country [52] 0 0
Czechia
State/province [52] 0 0
Brno Bohunice
Country [53] 0 0
Czechia
State/province [53] 0 0
Praha 10
Country [54] 0 0
Czechia
State/province [54] 0 0
Praha
Country [55] 0 0
France
State/province [55] 0 0
Caen
Country [56] 0 0
France
State/province [56] 0 0
Chambery cedex
Country [57] 0 0
France
State/province [57] 0 0
Le Mans
Country [58] 0 0
France
State/province [58] 0 0
Lille
Country [59] 0 0
France
State/province [59] 0 0
Paris
Country [60] 0 0
France
State/province [60] 0 0
Rennes
Country [61] 0 0
Germany
State/province [61] 0 0
Dresden
Country [62] 0 0
Germany
State/province [62] 0 0
Essen
Country [63] 0 0
Germany
State/province [63] 0 0
Frankfurt
Country [64] 0 0
Germany
State/province [64] 0 0
Giessen
Country [65] 0 0
Germany
State/province [65] 0 0
Greifswald
Country [66] 0 0
Germany
State/province [66] 0 0
Hannover
Country [67] 0 0
Germany
State/province [67] 0 0
Jena
Country [68] 0 0
Hong Kong
State/province [68] 0 0
Hong Kong
Country [69] 0 0
Hong Kong
State/province [69] 0 0
New Territories
Country [70] 0 0
Hungary
State/province [70] 0 0
Budapest
Country [71] 0 0
Hungary
State/province [71] 0 0
Debrecen
Country [72] 0 0
India
State/province [72] 0 0
Gujarat
Country [73] 0 0
India
State/province [73] 0 0
Maharashtra
Country [74] 0 0
India
State/province [74] 0 0
West Bengal
Country [75] 0 0
Italy
State/province [75] 0 0
BO
Country [76] 0 0
Italy
State/province [76] 0 0
FI
Country [77] 0 0
Italy
State/province [77] 0 0
RM
Country [78] 0 0
Italy
State/province [78] 0 0
TS
Country [79] 0 0
Italy
State/province [79] 0 0
VI
Country [80] 0 0
Japan
State/province [80] 0 0
Aichi
Country [81] 0 0
Japan
State/province [81] 0 0
Gifu
Country [82] 0 0
Japan
State/province [82] 0 0
Gunma
Country [83] 0 0
Japan
State/province [83] 0 0
Hokkaido
Country [84] 0 0
Japan
State/province [84] 0 0
Nagano
Country [85] 0 0
Japan
State/province [85] 0 0
Okayama
Country [86] 0 0
Japan
State/province [86] 0 0
Osaka
Country [87] 0 0
Japan
State/province [87] 0 0
Saitama
Country [88] 0 0
Japan
State/province [88] 0 0
Chiba
Country [89] 0 0
Japan
State/province [89] 0 0
Fukuoka
Country [90] 0 0
Malaysia
State/province [90] 0 0
Sarawak
Country [91] 0 0
Malaysia
State/province [91] 0 0
Johor Bahru
Country [92] 0 0
Malaysia
State/province [92] 0 0
Kuala Lumpur
Country [93] 0 0
Malaysia
State/province [93] 0 0
Penang
Country [94] 0 0
Malaysia
State/province [94] 0 0
Selangor
Country [95] 0 0
Mexico
State/province [95] 0 0
Mexico CP
Country [96] 0 0
Mexico
State/province [96] 0 0
Michoacan
Country [97] 0 0
Mexico
State/province [97] 0 0
Nuevo Leon
Country [98] 0 0
Norway
State/province [98] 0 0
Gralum
Country [99] 0 0
Romania
State/province [99] 0 0
District 2
Country [100] 0 0
Romania
State/province [100] 0 0
Bucharest
Country [101] 0 0
Romania
State/province [101] 0 0
Bucuresti
Country [102] 0 0
Singapore
State/province [102] 0 0
Singapore
Country [103] 0 0
Spain
State/province [103] 0 0
Andalucia
Country [104] 0 0
Spain
State/province [104] 0 0
Castilla Y Leon
Country [105] 0 0
Spain
State/province [105] 0 0
Catalunya
Country [106] 0 0
Spain
State/province [106] 0 0
Madrid
Country [107] 0 0
Spain
State/province [107] 0 0
Murcia
Country [108] 0 0
Thailand
State/province [108] 0 0
Bangkok
Country [109] 0 0
Thailand
State/province [109] 0 0
Chiang Mai
Country [110] 0 0
Turkey
State/province [110] 0 0
TUR
Country [111] 0 0
Turkey
State/province [111] 0 0
Aydin
Country [112] 0 0
Turkey
State/province [112] 0 0
Edirne
Country [113] 0 0
Turkey
State/province [113] 0 0
Istanbul
Country [114] 0 0
Turkey
State/province [114] 0 0
Izmir
Country [115] 0 0
Turkey
State/province [115] 0 0
Samsun
Country [116] 0 0
United Kingdom
State/province [116] 0 0
Cornwall
Country [117] 0 0
United Kingdom
State/province [117] 0 0
Birmingham
Country [118] 0 0
United Kingdom
State/province [118] 0 0
Glasgow
Country [119] 0 0
United Kingdom
State/province [119] 0 0
Leeds
Country [120] 0 0
United Kingdom
State/province [120] 0 0
Liverpool
Country [121] 0 0
United Kingdom
State/province [121] 0 0
London
Country [122] 0 0
United Kingdom
State/province [122] 0 0
Nottingham
Country [123] 0 0
United Kingdom
State/province [123] 0 0
Southampton
Country [124] 0 0
Vietnam
State/province [124] 0 0
Hanoi
Country [125] 0 0
Vietnam
State/province [125] 0 0
Ho Chi Minh

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Novartis Pharmaceuticals
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to evaluate the effect of two different doses of ianalumab versus placebo in addition to first-line corticosteroids in maintaining platelet count =30 G/L in adult participants with primary ITP.
Trial website
https://clinicaltrials.gov/study/NCT05653349
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Novartis Pharmaceuticals
Address 0 0
Novartis Pharmaceuticals
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Novartis Pharmaceuticals
Address 0 0
Country 0 0
Phone 0 0
1-888-669-6682
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT05653349